174 related articles for article (PubMed ID: 33834614)
1. COVID-19 vaccines and treatments: When speed is necessary and not enough.
Grasela TH; Price DA; Wagner JA
Clin Transl Sci; 2021 Jul; 14(4):1201-1205. PubMed ID: 33834614
[No Abstract] [Full Text] [Related]
2. [Fight against COVID-19: market overview and pipeline of ongoing trials].
Pontremoli R; Richard G; Vuddamalay G; Groux N
Med Sci (Paris); 2020 Dec; 36(12):1225-1232. PubMed ID: 33211647
[No Abstract] [Full Text] [Related]
3. [COVID-19: Warp Speed vaccines].
Feraoun Y; Maisonnasse P; Le Grand R; Beignon AS
Med Sci (Paris); 2021; 37(8-9):759-772. PubMed ID: 34080537
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
[TBL] [Abstract][Full Text] [Related]
5. Why Do We Still Lack a COVID-19 Vaccine? Searching for the Missing Pieces.
Perosa F; Favoino E; Prete M
Endocr Metab Immune Disord Drug Targets; 2021; 21(4):567-568. PubMed ID: 33290205
[No Abstract] [Full Text] [Related]
6. National responses to covid-19: drivers, complexities, and uncertainties in the first year of the pandemic.
Jung AS; Haldane V; Neill R; Wu S; Jamieson M; Verma M; Tan M; De Foo C; Abdalla SM; Shrestha P; Chua AQ; Bristol N; Singh S; Bartos M; Mabuchi S; Bonk M; McNab C; Werner GK; Panjabi R; Nordström A; Legido-Quigley H
BMJ; 2021 Nov; 375():e068954. PubMed ID: 34840138
[No Abstract] [Full Text] [Related]
7. COVID-19 vaccines: what do we know so far?
Dhillon P; Altmann D; Male V
FEBS J; 2021 Sep; 288(17):4996-5009. PubMed ID: 34288409
[TBL] [Abstract][Full Text] [Related]
8. The race to make a COVID-19 vaccine.
Boseley S
Lancet; 2021 Sep; 398(10303):832-833. PubMed ID: 34481566
[No Abstract] [Full Text] [Related]
9. Sensational media reporting is common when describing COVID-19 therapies, detection methods, and vaccines.
Ottwell R; Puckett M; Rogers T; Nicks S; Vassar M
J Investig Med; 2021 Aug; 69(6):1256-1257. PubMed ID: 34021053
[No Abstract] [Full Text] [Related]
10. Virology, epidemiology, immunology and vaccine development of SARS-CoV-2, update after nine months of pandemic.
Baay M; Lina B; Fontanet A; Marchant A; Saville M; Sabot P; Vandeputte J; Neels P
Biologicals; 2021 Jan; 69():76-82. PubMed ID: 33234420
[TBL] [Abstract][Full Text] [Related]
11. Ethical and Scientific Considerations Regarding the Early Approval and Deployment of a COVID-19 Vaccine.
Dal-Ré R; Caplan AL; Gluud C; Porcher R
Ann Intern Med; 2021 Feb; 174(2):258-260. PubMed ID: 33216636
[TBL] [Abstract][Full Text] [Related]
12. How to redesign COVID vaccines so they protect against variants.
Callaway E; Ledford H
Nature; 2021 Feb; 590(7844):15-16. PubMed ID: 33514888
[No Abstract] [Full Text] [Related]
13. COVID-19 vaccines: the importance of transparency and fact-based education.
Cohen AF; van Gerven J; Burgos JG; de Boer A; Foucher RAM; Flore H; Teitelbaum Z; van Eden W; Webb A; Cremers S
Br J Clin Pharmacol; 2020 Nov; 86(11):2107-2110. PubMed ID: 33464636
[No Abstract] [Full Text] [Related]
14. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients.
Amit S; Regev-Yochay G; Afek A; Kreiss Y; Leshem E
Lancet; 2021 Mar; 397(10277):875-877. PubMed ID: 33610193
[No Abstract] [Full Text] [Related]
15. Not in my backyard: COVID-19 vaccine development requires someone to be infected somewhere.
Heriot GS; Jamrozik E
Med J Aust; 2021 Mar; 214(4):150-152.e1. PubMed ID: 33550606
[No Abstract] [Full Text] [Related]
16. Why do SARS-COV vaccines not exist? The pharma scientific intelligence and business model must be revisited!
Boudjelal M; Nehdi A; Islam I
Expert Opin Drug Discov; 2020 Nov; 15(11):1233-1235. PubMed ID: 32543297
[No Abstract] [Full Text] [Related]
17. New WTO leader faces COVID-19 challenges.
Zarocostas J
Lancet; 2021 Feb; 397(10276):782. PubMed ID: 33640051
[No Abstract] [Full Text] [Related]
18. COVID-19 in 2022: controlling the pandemic is within our grasp.
Van Kerkhove MD
Nat Med; 2021 Dec; 27(12):2070. PubMed ID: 34907391
[No Abstract] [Full Text] [Related]
19. Free licensing of vaccines to end the COVID-19 crisis.
Bozorgmehr K; Jahn R; Stuckler D; McKee M
Lancet; 2021 Apr; 397(10281):1261-1262. PubMed ID: 33743843
[No Abstract] [Full Text] [Related]
20. Transforming vaccine development.
Black S; Bloom DE; Kaslow DC; Pecetta S; Rappuoli R
Semin Immunol; 2020 Aug; 50():101413. PubMed ID: 33127296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
